Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Pharmacother. 2011 Feb;12(3):435-41. doi: 10.1517/14656566.2011.521153. Epub 2011 Jan 14.

Pharmacoeconomic evaluation of warfarin pharmacogenomics.

Author information

1
Centre for Pharmacoeconomics Research, School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, NT, Hong Kong. joyceyou@cuhk.edu.hk

Abstract

INTRODUCTION:

the merit of applying pharmacogenomics in the induction phase of warfarin therapy for personalized dosing is controversial and highly dependent on its cost-effectiveness.

AREAS COVERED:

published studies on pharmacoeconomics of warfarin pharmacogenomic application are reviewed. A literature search was done using Medline and Embase covering the period 2000 - 2010. Decision tree and Markov modeling were the most frequently used methods in the reviewed reports. Studies incorporating clinical efficacy data of genotype-guided dosing algorithm had shown that warfarin pharmacogenomics would improve quality-adjusted life-years (QALYs) gained. Nevertheless, it was unlikely to be cost-effective for general patients. Influential factors to improve the cost-effectiveness included low genotyping cost, high effectiveness in improving anticoagulation control/event rate, and applying warfarin pharmacogenomics to patients with high bleeding risk or at practice sites with suboptimal management of anticoagulation control.

EXPERT OPINION:

warfarin pharmacogenomics would improve QALYs and could possibly be cost-effective in selected patient groups or practice sites.

PMID:
21231897
DOI:
10.1517/14656566.2011.521153
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center